TCRX$0.174510.47%-0.0204
After Hours: 0.19+0.02 +8.88%
Tscan Therapeutics Inc (TCRX)
Date: 2026-10-30 16:00O: 0.1925H: 0.1925L: 0.1732C: 0.1745Vol: 333.2k
Tscan Therapeutics Inc stock is traded at $0.1745, with a volume of 333,158. It is down -10.47% in the last 24 hours and down -44.52% over the past month. TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Previous Close:
$0.1949
Open:
$0.1925
24h Volume:
333,158
Relative Volume:
0.78
Market Cap:
$11.83M
Revenue:
$9.14M
Net Income/Loss:
-$124.31M
P/E Ratio:
-
EPS:
-$0.9573
Net Cash Flow:
-$125.43M
1W Performance:
-14.12%
1M Performance:
-44.52%
6M Performance:
-84.96%
1Y Performance:
-90.62%
1-Day Range:
$0.1732$0.1925
1-Week Range:
$0.1732$0.2004
52-Week Range:
$0.1732$2.01
Tscan Therapeutics Inc Stock (TCRX) Company Profile
Name
Tscan Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
857-399-9500Address
830 WINTER STREET, WALTHAM, USACompare TCRX vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TCRX Tscan Therapeutics Inc | $0.1745 | $11.83M | $9.14M | -$124.31M | -$125.43M | -$0.9573 |
 VRTX Vertex Pharmaceuticals Inc | $558.88 | $141.65B | $12.34B | $4.34B | $3.71B | $16.87 |
 REGN Regeneron Pharmaceuticals Inc | $927.89 | $95.53B | $14.92B | $4.42B | $3.79B | $41.04 |
 MRNA Moderna Inc | $221.72 | $88.52B | $2.23B | -$3.19B | -$1.60B | -$8.15 |
 ARGX Argen X Se Adr | $892.87 | $56.15B | $4.16B | $1.29B | $734.26M | $19.58 |
 ONC Beone Medicines Ltd Adr | $370.33 | $41.89B | $5.76B | $514.49M | $1.10B | $4.48 |
Tscan Therapeutics Inc Stock (TCRX) Upgrades & Downgrades
Tscan Therapeutics Inc Stock (TCRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Tscan Therapeutics Inc Stock (TCRX) Insider Trading
- Lynx1 Capital Management LPDec 23 '2510% Owner
- Transaction
- Buy
- Cost
- $0.9
- #Shares
- 6,232
- Value ($)
- 5,602
- #Shares Total
- 8,019,148
- Lynx1 Capital Management LPDec 22 '2510% Owner
- Transaction
- Buy
- Cost
- $0.9
- #Shares
- 75,500
- Value ($)
- 67,950
- #Shares Total
- 8,012,916
